Journal of Translational Medicine Impact Factor

The similar titles create a common lookup error. Journal of Translational Medicine is the Springer Nature/BioMed Central open-access journal with ISSN 1479-5876 and a 2025 JIF of 9.7. Science Translational Medicine is a separate AAAS journal with its own editorial model and metric record.

Before quoting a metric in a CV, manuscript, or journal shortlist, match all three fields: the full journal title, the ISSN, and the publisher. A close title match is not enough.

This is more than a naming detail. The observed query was previously associated

with the AAAS journal's metric page. That page can be accurate about **Science

Translational Medicine** and still be a poor answer for a researcher checking

the separate Springer title. The correct repair is one exact owner, not a

broader page that treats both journals as synonyms.

In our analysis of the final June 13 to July 10 Search Console window, the

exact query generated 2,345 impressions while the unrelated AAAS title page

appeared at an average position of 8.5. We trace each title collision through

the title, ISSN, publisher, slug inventory, ownership registry, and canonical

map before assigning an owner. This is a named failure pattern: near-identical

journal titles can shift exact metric demand to a correct but unrelated URL. In

practice, matching the ISSN and publisher is more reliable than trusting a

partial title match.

The Journal Impact Factor is a journal-level citation average. It can help place Journal of Translational Medicine in a translational-research shortlist, but it cannot determine whether a particular paper has the evidence, clinical relevance, or audience fit to survive editorial review.

The publisher describes the journal as interdisciplinary and dedicated to turning fundamental discoveries in basic and preclinical sciences into improvements in human health. That gives authors a more useful test than the JIF: can the manuscript show a credible bridge from the biological, mechanistic, or preclinical result toward a human-health consequence?

The bridge has to be supported by the paper rather than supplied by optimistic language. A detailed basic-science study can be strong yet still need a clearer translational rationale. A clinically motivated study can also miss fit if the mechanism, biomarker logic, or intervention evidence is not sufficiently developed. The metric does not resolve either issue. It is context, not a substitute for reading the manuscript.

Use this short source check when the JIF will appear in a CV, cover letter,

grant document, or journal shortlist:

The publisher page makes the current metric unusually easy to verify because it

displays both the JIF and the five-year JIF on the journal profile. For a formal

rank, percentile, or category claim, however, use the licensed JCR title record

instead of copying an unqualified search result.

A current public JCR-derived record lists 7.5 for 2024 and Springer reports 9.7 for 2025. The current JIF is up from 7.5 by 2.2 year-over-year. Treat that one-year comparison as limited context, not a forecast: publication volume, citation timing, and field behavior can all affect a journal metric.

The publisher profile is the source for the current 9.7 value. Do not reconstruct a longer trend from search snippets or mix historical values from different directories. For a formal rank, percentile, or multi-year JIF analysis, verify the full title record in licensed Clarivate JCR.

Use the metric to understand the journal's citation context, then switch to the journal's scope and recent articles for the actual fit decision. The journal welcomes work across translational research and organizes specialized sections with their own expert editors and editorial boards. That breadth does not remove the need for a clear translational story.

The publisher profile is the reliable place to verify the current editorial

team and submission path. Editorial appointments and portal requirements can

change, so do not quote an individual editor's name in a cover letter without

checking the live journal profile first.

Before submitting, ask:

• Does the paper explain how the fundamental or preclinical result could improve human health, rather than merely mention a disease context?
• Are the methods and evidence strong enough for the causal or translational claim in the abstract?
• Would a reader outside the immediate specialty understand what changes because of the result?
• Does the article type and manuscript package match the live author instructions?
• Has the corresponding author checked the current open-access funding terms before submission?

For a broad venue comparison, use how to choose the right journal for a paper. For a metric-source check across titles, use the journal impact-factor lookup guide.

Springer reports a median of 11 days from submission to first decision. It is helpful for planning, but it is not a service-level promise and does not mean every paper reaches external review in that time. A first decision can include an editorial decline, a request for changes before review, or a decision after reviewer input.

Use the median as a planning signal only. Do not infer that a manuscript is favored or disadvantaged from a small deviation around it, and do not turn a journal-wide median into a prediction for a specific editor, article type, or reviewer pool.

The publisher profile is the source for the current 9.7 value. The historical

series below is transcribed from an academic-library journal record that lists

the exact ISSN and its JCR-JIF and quartile fields through 2024. Keep the 2025

JIF separate because it was released in the 2026 JCR cycle.

The series is useful for direction, not for mixing metric cycles. For a formal

rank, percentile, or multi-year JIF analysis, verify the full title record in

licensed Clarivate JCR.